ViaCyte CEO to present at Cell & Gene Meeting

By The Science Advisory Board staff writers

October 8, 2021 -- ViaCyte will present data on the latest product candidates the company is developing to treat type 1 diabetes at the Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa on October 14 at 10:15 a.m. PST.

Michael Yang, the company's chief executive officer, will discuss ViaCyte's clinical proof of concept indicating that its stem cell-derived islet replacement therapy may potentially produce insulin and regulate blood glucose in patients with type 1 diabetes.

Copyright © 2021

BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Laboratory Products Association Annual Meeting
October 1-4
Scottsdale, Arizona United States
Cell & Gene Meeting on the Mesa
October 11-13
Carlsbad, California United States
IDWeek 2022
October 19-23
District of Columbia United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter